Overview
- The Ethics and Public Policy Center (EPPC) study reports a 10.9% serious adverse event rate for mifepristone, significantly higher than FDA figures.
- Conservative lawmakers, including Senator Josh Hawley, are urging the FDA to reinstate stricter pre-pandemic safety protocols for the abortion pill.
- Medical experts, including the American College of Obstetricians and Gynecologists, criticize the study as flawed, citing misclassification of normal outcomes as adverse events.
- The study's findings align with some mifepristone label data but lack peer review, raising questions about its credibility and scientific rigor.
- The debate underscores broader tensions over abortion access and the politicization of healthcare data in the post-Dobbs era.